33. Investigating Cardiotoxicity in a 3-Drug Comparison for the Treatment of COVID19 with AnaBios's Dr. Najah Abi-Gerges

In this episode, Legal Drugs Podcast Host, Angela Stoyanovitch, speaks with Dr. Najah Abi-Gerges, head of AnaBios Corporation's R&D. Najah walks the audience through recent publications in collaboration with big pharma on the cardiotoxicity effects of three drugs that have been posed to treat COVID19. Cardiotoxicity studies are an important step in understanding the safety of a legal drug.  AnaBios uses their early-stage discovery and translational research model to test and compare Hydroxychloroquine, Chloroquine and Azithromycin in adult human primary cardiomyocytes. Cardio safety is especially personal to both Angela and Najah as both speak about their family history with heart disease.  More importantly, for areas and parts of the world where COVID vaccines will not be made available or accessible, viable treatments need to be accessed for potential risks in order to provide the best alternatives.  Link to Scientific Report article, NIH & FDA press releases from AnaBios;  NIH/NCATS Awards SBIR Grant to AnaBios FDA Inks Research Collaboration with AnaBios FDA Awards AnaBios Contract   This episode edited and produced by Margaret Beveridge.